drugset / Trial / NCT06653023

Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer

NCT06653023

Phase 0 Suspended 60 enrolled Wondercel Biotech (ShenZhen)
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.

Timeline

Start
2024-10-23
Primary completion
2027-10-20
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject REVO-UWD-03 Cell therapy Other
Background Mycophenolate Sodium Unknown 1440 mg Oral